Teva Pharmaceutical Industries Limited beat EPS estimates 75% of the time across 16 reported quarters (12 beats, 4 misses), averaging -0.3% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $0.05 | $0.00 | -100.0% | Miss | Q2 FY26 call · transcript |
| Q1 FY26 | $0.49 | $0.50 | +2.0% | Beat | |
| Q4 FY25 | $0.63 | $0.93 | +47.6% | Beat | Q4 FY25 call · transcript |
| Q3 FY25 | $0.66 | $0.75 | +13.6% | Beat | |
| Q2 FY25 | $0.60 | $0.64 | +6.7% | Beat | |
| Q1 FY25 | $0.47 | $0.49 | +4.3% | Beat | |
| Q4 FY24 | $0.66 | $0.70 | +6.1% | Beat | |
| Q3 FY24 | $0.63 | $0.67 | +6.3% | Beat | |
| Q2 FY24 | $0.55 | $0.58 | +5.5% | Beat | |
| Q1 FY24 | $0.49 | $0.46 | -6.1% | Miss | |
| Q4 FY23 | $0.73 | $0.98 | +34.3% | Beat | |
| Q3 FY23 | $0.57 | $0.58 | +1.8% | Beat |
Back to TEVA overview · TEVA holders · TEVA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.